Depsipeptide in Treating Patients With Solid Tumors
NCT00019318 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2015-04-29
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of depsipeptide in treating patients who have solid tumors for which no standard therapy exists.
Conditions
Interventions
- DRUG
-
romidepsin
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Susan E. Bates, MD · National Cancer Institute (NCI)
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-08-31
Countries
- United States
Study Locations
More Related Trials
-
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT01590732 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
NCT00426764 ·Status: COMPLETED ·Phase: PHASE2
-
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
NCT01445340 ·Status: TERMINATED ·Phase: PHASE1
-
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT00084461 ·Status: TERMINATED ·Phase: PHASE2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
NCT02232516 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
NCT04774068 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
NCT00106431 ·Status: COMPLETED ·Phase: PHASE2
-
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
NCT01998035 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
NCT01846390 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
NCT03141203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
NCT02181218 ·Status: COMPLETED ·Phase: PHASE1
-
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
NCT01851369 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
NCT01908777 ·Status: COMPLETED ·Phase: PHASE2
-
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
NCT00354185 ·Status: TERMINATED ·Phase: PHASE1
-
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
NCT00101244 ·Status: TERMINATED ·Phase: PHASE1
-
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
NCT03534180 ·Status: COMPLETED ·Phase: PHASE2
-
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00323934 ·Status: COMPLETED ·Phase: PHASE1
-
Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma
NCT00002745 ·Status: COMPLETED ·Phase: PHASE2
-
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
NCT03484819 ·Status: COMPLETED ·Phase: PHASE2
-
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
NCT04233697 ·Status: WITHDRAWN ·Phase: PHASE1
-
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
NCT00695448 ·Status: TERMINATED ·Phase: PHASE1
-
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
NCT00089271 ·Status: COMPLETED ·Phase: PHASE1
-
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
NCT05490771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
NCT03017820 ·Status: RECRUITING ·Phase: PHASE1